| MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches N Amodio, L Raimondi, G Juli, MA Stamato, D Caracciolo, P Tagliaferri, ... Journal of hematology & oncology 11, 1-19, 2018 | 293 | 2018 |
| Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity N Amodio, MA Stamato, G Juli, E Morelli, M Fulciniti, M Manzoni, E Taiana, ... Leukemia 32 (9), 1948-1957, 2018 | 213 | 2018 |
| Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity L Raimondi, N Amodio, MT Di Martino, E Altomare, M Leotta, ... Oncotarget 5 (10), 3039, 2014 | 124 | 2014 |
| Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts MR Pitari, M Rossi, N Amodio, C Botta, E Morelli, C Federico, A Gullà, ... Oncotarget 6 (29), 27343, 2015 | 112 | 2015 |
| In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells MT Di Martino, A Gullà, ME Gallo Cantafio, E Altomare, N Amodio, ... PloS one 9 (2), e89659, 2014 | 102 | 2014 |
| Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma MA Stamato, G Juli, E Romeo, D Ronchetti, M Arbitrio, D Caracciolo, ... Oncotarget 8 (63), 106527, 2017 | 67 | 2017 |
| From single level analysis to multi-omics integrative approaches: a powerful strategy towards the precision oncology MEG Cantafio, K Grillone, D Caracciolo, F Scionti, M Arbitrio, V Barbieri, ... The Road from Nanomedicine to Precision Medicine, 829-869, 2019 | 62 | 2019 |
| MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells C Botta, M Cuce, MR Pitari, D Caracciolo, A Gulla, E Morelli, C Riillo, ... Leukemia 32 (4), 1003-1015, 2018 | 62 | 2018 |
| Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 E Morelli, L Biamonte, C Federico, N Amodio, MT Di Martino, ... Blood, The Journal of the American Society of Hematology 132 (10), 1050-1063, 2018 | 61 | 2018 |
| Pharmacogenomics biomarker discovery and validation for translation in clinical practice M Arbitrio, F Scionti, MT Di Martino, D Caracciolo, L Pensabene, ... Clinical and Translational Science 14 (1), 113-119, 2021 | 59 | 2021 |
| miRNAs and lncRNAs as novel therapeutic targets to improve cancer immunotherapy MT Di Martino, C Riillo, F Scionti, K Grillone, N Polerà, D Caracciolo, ... Cancers 13 (7), 1587, 2021 | 58 | 2021 |
| miR-22 suppresses DNA ligase III addiction in multiple myeloma D Caracciolo, MT Di Martino, N Amodio, E Morelli, M Montesano, C Botta, ... Leukemia 33 (2), 487-498, 2019 | 53 | 2019 |
| Mir-221/222 are promising targets for innovative anticancer therapy MT Di Martino, M Rossi, D Caracciolo, A Gullà, P Tagliaferri, P Tassone Expert Opinion on Therapeutic Targets 20 (9), 1099-1108, 2016 | 53 | 2016 |
| Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma MT Di Martino, PH Guzzi, D Caracciolo, L Agnelli, A Neri, BA Walker, ... Oncotarget 6 (22), 19132, 2015 | 52 | 2015 |
| From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario M Rossi, N Amodio, M Teresa Di Martino, D Caracciolo, P Tagliaferri, ... Current drug targets 14 (10), 1144-1149, 2013 | 52 | 2013 |
| miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review MT Di Martino, M Arbitrio, D Caracciolo, A Cordua, O Cuomo, K Grillone, ... Molecular Therapy-Nucleic Acids 27, 1191-1224, 2022 | 50 | 2022 |
| miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma M Rossi, E Altomare, C Botta, ME Gallo Cantafio, S Sarvide, D Caracciolo, ... Leukemia 35 (3), 823-834, 2021 | 46 | 2021 |
| Alternative non-homologous end-joining: error-prone DNA repair as cancer’s achilles’ heel D Caracciolo, C Riillo, MT Di Martino, P Tagliaferri, P Tassone Cancers 13 (6), 1392, 2021 | 41 | 2021 |
| Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma D Caracciolo, F Scionti, G Juli, E Altomare, G Golino, K Todoerti, ... Haematologica 106 (1), 185, 2021 | 39 | 2021 |
| Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma N Amodio, ME Gallo Cantafio, C Botta, V Agosti, C Federico, D Caracciolo, ... Cancers 11 (2), 236, 2019 | 36 | 2019 |
Pierosandro Tagliaferriprofessore di oncologia medica Università magna graecia di Catanzaro在 unicz.it 的电子邮件经过验证
